Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Zydus Lifesciences Limited
Press Release Apr 20 2024
Business
Apr 20 2024
5 min read

Press Release Apr 20 2024

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 20, 2024, titled "Sentynl Therapeutics receives marketing authorization for NULIBRY?? (fosdenopterin) from the UK MHRA for treatment of MoCD Type A".

View Attachment